iRIS serves oncology trials at Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, and other affiliated institutions.
|
|
Dear DF/HCC Research Community,
Today, June 18, a new iRIS feature will be implemented to enable automatic email reminders for pending conditions that are awaiting a response. Please review the details below for more information.
|
|
What is changing?
- Starting Friday, June 18, iRIS will begin sending automatic email reminders to study teams when conditions or corrections have been pending a response for 15 calendar days.
- If the same conditions remain pending, a second reminder will be sent at 30 days and a final reminder at 60 days.
- Submissions that have outstanding conditions for 90 days or more may be subject to withdrawal.
|
|
Who will receive the reminder emails?
- The reminder emails will be sent to the Core Site PI and Study Contacts listed in iRIS at the time the notification is sent.
- As a reminder, all pending tasks (including pending responses to conditions) are visible to Study Contacts on their Task List when logging into iRIS.
|
|
Will reminders be sent for all types of submissions?
- On June 18, automatic reminders will be enabled only for core site submissions associated with a protocol. This will include new protocols, amendments, dose/cohort forms, etc.
- We will work to enable similar reminders for subsite submissions and special submission forms in the future.
- Reminders will be sent for all types of pending conditions, including those from SRC, IRB, feasibility reviewers, ancillary reviewers and ODQ activation.
|
|
Will reminders be sent for submissions that are currently pending a response?
- Yes. A reminder will be sent for any conditions that reach 15, 30, or 60 days pending after June 18.
- This means some research teams may receive a 30- or 60-day notice without first having received a 15-day reminder.
|
|
Oncology trials in Boston are a collaborative effort involving many from many institutions. iRIS represents an opportunity to streamline all of the processes involved, and move trials from submission to activation, and to our patients, more quickly. Please take advantage of all of the provided information and resources to help us make this system as efficient to use as possible.
Sincerely,
|
|
|
|
Jeffrey Meyerhardt, MD, MPH
Associate Director for Clinical Trials,
Dana-Farber/Harvard Cancer Center
|
|
|
|
Drew Memmott
Associate Director for Administration,
Dana-Farber/Harvard Cancer Center
|
|
|
|
Erica Woulf
Senior Director for Research Informatics Operations,
Dana-Farber/Harvard Cancer Center
|
|
|
|
|
|
|
